# Compare GLOW and Melanotan II — Peptide Rejuvination

> A side-by-side comparison of two Skin & Aesthetics research peptides — GLOW and Melanotan II — across mechanism, most-studied application, evidence maturity, administration, regulatory status, and key caution.

How a three-peptide tissue-repair blend and a single-receptor melanocortin agonist differ in mechanism, evidence maturity, and what each is actually studied for.

## The short version

This page lines up [GLOW](/glow) and [Melanotan II](/melanotan-2) on the dimensions that matter most when reading skin-and-aesthetics peptide research: mechanism, most-studied application, evidence maturity, administration studied, regulatory status, and the single most important caution for each. The short version: both sit under the same 'skin and aesthetics' research umbrella, and neither is an approved medicine, but they could hardly work more differently. GLOW is a three-peptide combination aimed at skin and tissue structure, built on constituent literatures that are themselves mostly preclinical or small pilot studies. Melanotan II is a single, engineered molecule aimed at skin pigment through one well-characterized receptor pathway, with real (if old and incomplete) controlled human trial data. Nothing here is medical advice, and no dose is recommended for any person.

## The comparison matrix

| Dimension | GLOW (research blend) | Melanotan II |
| --- | --- | --- |
| Peptide class | Combination: copper-binding tripeptide (GHK-Cu) + gastric pentadecapeptide (BPC-157) + thymosin beta-4 fragment (TB-500) | Cyclic heptapeptide analog of alpha-MSH; non-selective melanocortin receptor (MC1R-MC5R) agonist |
| Most-studied in | Wound and tendon healing, angiogenesis, and skin matrix remodeling — each constituent studied separately [3][4][5][6][7] | Skin/hair pigmentation, appetite suppression, and male erectile function [9][12] |
| Evidence base | Mostly preclinical and small human pilot studies per constituent; the blend itself untested [1][2] | Small controlled human trials from the 1990s-2020s; growing modern case-report record [8][10][12] |
| Administration studied | Subcutaneous injection (constituent studies) | Subcutaneous injection (controlled trials and case reports) [8][12] |
| Regulatory status | Not FDA-approved as a blend; GHK-Cu (topical) is a cosmetic ingredient, BPC-157 and TB-500 are unapproved research chemicals; TB-500 is WADA-prohibited | Not approved by the FDA or any regulator for any use; never completed Phase 2/3 development [11] |
| Key caution | Angiogenic constituents raise a theoretical concern for active cancer; the three-peptide mixture has no combined safety data [1][3] | Documented case reports of new/changing moles, renal injury, and priapism; unregulated supply [10] |

## Mechanism and target

GLOW and Melanotan II act on almost entirely different biological systems. GLOW's three constituents target the skin's structural and repair machinery: GHK-Cu signals dermal fibroblasts to build collagen, elastin and glycosaminoglycans [4][5]; BPC-157 up-regulates VEGFR2 to drive new blood-vessel growth [3]; TB-500 sequesters actin to promote cell migration into damaged tissue [7]. None of these three mechanisms touches pigment production.

Melanotan II targets pigment production directly, and does so non-selectively. Activating MC1R on melanocytes triggers the cAMP-PKA-CREB-MITF cascade that drives melanin synthesis — the pigmentation mechanism. But because Melanotan II is not selective for MC1R, it also activates MC3R and MC4R in the brain, producing the appetite-suppressing and pro-erectile effects documented in both animal and human studies [9][12]. That non-selectivity is the mechanistic reason a 'tanning peptide' also changes appetite and sexual function — a single receptor family, several downstream jobs.

## Most-studied application

GLOW's constituent literature centers on tissue repair: tendon healing and angiogenesis for BPC-157 [3][6], wound re-epithelialization and cell migration for TB-500 [7], and collagen/matrix synthesis with cosmetic skin outcomes for GHK-Cu [4][5]. A 2026 review is the only source that discusses all three together, and even it stops short of testing the combination [1].

Melanotan II's controlled human studies center on two outcomes: appetite/food-motivation effects, studied directly in animal reward-circuit models [9], and erectile function, studied in a placebo-controlled human crossover trial [12]. Its pigmentation effect — the reason it is used at all — is documented mechanistically and in case reports [8] rather than in a dedicated controlled efficacy trial for tanning specifically.

## Evidence base and maturity

This is where the two genuinely diverge. GLOW's evidence is a patchwork of single-constituent studies, most of them preclinical (rodent and cell-culture models), with BPC-157's human data limited to three small pilot studies [2] and no study of the combination product at all [1]. Melanotan II has a small but real controlled human trial base — a 10-person double-blind crossover study for erectile function [12] — but that base is thirty years old, was never carried through Phase 2/3 development, and predates the modern case-report literature describing pigmentation and kidney harms [8][10]. Put plainly: GLOW's uncertainty is about whether preclinical, single-constituent signals hold up as a combination product; Melanotan II's uncertainty is about a compound with real but old and incomplete efficacy data, now accumulating a documented safety record that outpaces its approval status.

## Regulatory and legal status

Neither compound is an FDA-approved medicine. Within GLOW, topical Copper Tripeptide-1 (GHK-Cu) is a legal cosmetic ingredient, but BPC-157 and TB-500 are unapproved research chemicals, and TB-500, as the thymosin beta-4 fragment, is prohibited in sport under the WADA Prohibited List at all times. Melanotan II has never been approved anywhere and never completed late-stage clinical development; two separate melanocortin compounds derived from related research — one for a rare skin condition, one for sexual desire disorder — were later approved, but those approvals do not extend to Melanotan II itself [11].

## Key caution for each

For GLOW, the defining caution is that the blend has never been tested as a unit — every safety and efficacy claim is inherited from one of its three constituents, and the pro-angiogenic constituents raise a theoretical, mechanistic concern for anyone with active or recent cancer [1][3]. For Melanotan II, the defining caution is the modern case-report record: new or changing moles, kidney injury, and priapism, arising from a compound that never completed controlled clinical development and is now used almost entirely as unregulated, unverified supply [10]. Read together, the pattern is that neither compound's real-world use is backed by the kind of rigorous, combination- or product-level evidence its marketing implies.

---

A clinician's-briefing digest of skin-remodeling and pigmentation research peptides — no products, no prescriptions, just the literature.